Jun 25, 2017 08:02 am UTC| Business
FRUTAROM ACQUIRES 80% OF SDFLC, A LEADING BRAZILIAN PRODUCER OF TASTE SOLUTIONS IN THE FIELD OF ICE CREAM AND DESSERTS, FOR BRL 110 M (APPROX. USD 33 M) SALES OF BRL 72 M (APPROX. USD 22 M) FOR SDFLC IN THE 12 MONTH...
Jun 24, 2017 22:14 pm UTC| Business
Miami Beach, FL, June 24, 2017 -- Incoming U.S. Conference of Mayors (USCM) President Mayor Mitch Landrieu of New Orleans joined dozens of mayors from across the country to urge Americans to move past Washington’s...
Survey finds U.S. mayors taking action on climate protection, and planning for more
Jun 24, 2017 21:41 pm UTC| Business
Miami Beach, FL, June 24, 2017 -- Cities across the country are showing leadership in promoting renewable electricity, low-carbon transportation, and energy efficiency, according to preliminary results of a survey...
LOS ANGELES & HATTIESBURG DEEMED “MOST LIVABLE” CITIES IN AMERICA
Jun 24, 2017 21:20 pm UTC| Business
Miami Beach, FL, June 24, 2017 -- Los Angeles Mayor Eric Garcetti and Hattiesburg, MS Mayor Johnny DuPree have been awarded first place honors in the 2017 City Livability Awards Program during The U.S. Conference of...
United for Human Rights Center Creating Awareness and Protecting Children from Human Trafficking
Jun 24, 2017 17:38 pm UTC| Business
CLEARWATER, Fla., June 24, 2017 -- On the 21st of June, Pinellas County Sheriff’s Deputy Jessica Hughey spoke to parents and educators at the United for Human Rights (UHR) Center in Downtown Clearwater on “Internet...
Clean your PC today - Top reasons why
Jun 24, 2017 14:51 pm UTC| Business
If youre the kind of person that likes to wait until they dont have any more free space on their device before they decide to do something about it, youre probably having a miserable time with your machines performance....
Jun 24, 2017 12:05 pm UTC| Business
Inclusion of Phase 2 Expansion Data Demonstrates Overall Efficacy and Safety Profile Consistent with Previously Reported Data In 214 R/R AML Patients Treated with Enasidenib at 100 mg Daily Dose in Phase 1/2 Trial, 20.1%...